Lexaria Bioscience (LEXX) Income from Continuing Operations (2017 - 2026)

Lexaria Bioscience has disclosed Income from Continuing Operations across 10 years of filings, most recently posting 1452732.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 1452732.0, up 47.19% year-over-year; the trailing twelve-month figure through Feb 2026 was 9464154.0 (down 0.89% YoY), and the FY2025 annual result was 11877720.0, down 106.97% from the prior year.
• Income from Continuing Operations came in at 1452732.0 for Q1 2026 at Lexaria Bioscience, up from 1575410.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 668006.0 in Q1 2024 to a low of 3750231.0 in Q2 2025.
• The 5-year median for Income from Continuing Operations is 1695419.0 (2022), against an average of 1870250.65.
• Across the five-year window, Income from Continuing Operations surged 49.53% in 2024 and plunged 311.82% in 2025, its largest moves.
• Lexaria Bioscience's Income from Continuing Operations stood at 1695419.0 in 2022, then soared by 33.24% to 1131823.0 in 2023, then plunged by 137.73% to 2690696.0 in 2024, then jumped by 41.45% to 1575410.0 in 2025, then rose by 7.79% to 1452732.0 in 2026.
• The last three Income from Continuing Operations figures came in at 1452732.0 (Q1 2026), 1575410.0 (Q4 2025), and 2685781.0 (Q3 2025), per Business Quant data.